| Pemetrexed in front-line chemotherapy for advanced non-small-cell lung cancer. | |
| | |
MedLine Citation:
|
PMID: 15655934 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Pemetrexed (Alimta) possesses broad antitumor activity. It has been evaluated in non-small-cell lung cancer (NSCLC) as front-line chemotherapy in a comprehensive phase II evaluation. While various antifolates have been previously evaluated in clinical trials, drug development was stopped or delayed in light of their lack of efficacy or occurrence of life-threatening toxicities. While similar trends were observed with pemetrexed early in development, investigators instituted folic acid and vitamin B12 supplementation to minimize these toxicities without hampering drug efficacy. This article briefly summarizes the current evidence that supports the role of pemetrexed-based combinations in clinical trials for chemonaive patients with advanced NSCLC. |
| | |
Authors:
|
Giorgio V Scagliotti; Silvia Novello; Lucio Crino; Rafael Rosell |
Related Documents
:
|
17205204 - Pharmacotherapy for fecal incontinence: a review. 20348494 - Treatment with coartem (artemether-lumefantrine) in papua new guinea. 20401974 - Mutation-driven drug development in melanoma. 15544204 - Evidence-based evaluation of immunomodulatory therapy for the cutaneous manifestations ... 21711774 - Novel docetaxel-loaded nanoparticles based on poly(lactide-co-caprolactone) and poly(la... 14708054 - Special wound healing methods used in ancient egypt and the mythological background. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Oncology (Williston Park, N.Y.) Volume: 18 ISSN: 0890-9091 ISO Abbreviation: Oncology (Williston Park, N.Y.) Publication Date: 2004 Nov |
Date Detail:
|
Created Date: 2005-01-19 Completed Date: 2005-02-03 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8712059 Medline TA: Oncology (Williston Park) Country: United States |
Other Details:
|
Languages: eng Pagination: 32-7 Citation Subset: IM |
Affiliation:
|
University of Torino, Department of Clinical & Biological Sciences, S. Luigi Gonzaga Thoracic Oncology Unit, Orbassano (Torino), Italy. giorgio.scagliotti@unito.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Combined Chemotherapy Protocols
/
therapeutic use Carcinoma, Non-Small-Cell Lung / drug therapy*, pathology Cisplatin / administration & dosage Clinical Trials, Phase II as Topic Female Folic Acid Antagonists / administration & dosage* Glutamates / administration & dosage* Guanine / administration & dosage*, analogs & derivatives* Humans Lung Neoplasms / drug therapy*, pathology Neoplasm Metastasis Thymidylate Synthase / antagonists & inhibitors* |
| Chemical | |
Reg. No./Substance:
|
0/Folic Acid Antagonists; 0/Glutamates; 137281-23-3/pemetrexed; 15663-27-1/Cisplatin; 73-40-5/Guanine; EC 2.1.1.45/Thymidylate Synthase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Pemetrexed in malignant pleural mesothelioma.
Next Document: Pemetrexed in second-line treatment of non-small-cell lung cancer.